FDA Approves RSV Shot Despite High Infant Risk - AI Podcast
Dr. Joseph Mercola - Take Control of Your Health · Dr. Joseph Mercola
July 17, 20258m 48s
Audio is streamed directly from the publisher (traffic.libsyn.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
Story at-a-glance
- Merck's respiratory syncytial virus (RSV) shot clesrovimab (Enflonsia) was approved even though 11.71% of babies in the trial experienced serious adverse events, including seizures, brain injury, and death
- Infants who got clesrovimab had a 350% higher risk of upper respiratory infections — exactly the type of illness this shot claims to prevent
- The injection is given in a single, fixed dose regardless of infant weight, putting smaller, younger babies at greater risk due to disproportionately high exposure
- Babies who received the shot had a threefold increase in severe neurological reactions compared to those given a placebo
- Only about 25 babies in the U.S. succumb to RSV each year, making the known risks of clesrovimab far outweigh the threat the virus poses to most children